The Day In Review: Rumors Ravage Biotech

April 22, 2005 -- Stocks went into a freefall late in Friday’s session, following news that North Korea might test a nuclear weapon soon. By the closing bell, prices recovered some, though not all, of their drop. The Centient Biotech 200 fell 28 points to close at 3179.86, a drop of .87%. The NYSE Composite proved the most elastic in recovering its losses, sliding just .47%, while Nasdaq was off 1.54%. A European advisory board recommended Temodal, a Schering-Plough drug, for first-line treatment of brain cancer, Immune Response said its HIV immune therapy drug Remune shows encouraging data, Synta files for an IPO, Anadys files a $75 million shelf registration, Amgen beats the street (though the street does not seem impressed) and Serono took a large charge to settle medicare pricing abuse allegations, an unfortunate suprise. More details...

Back to news